ArticlePharmacoEconomics - open2022

Cost-Effectiveness Analysis of Ofatumumab for the Treatment of Relapsing-Remitting Multiple Sclerosis in Canada.

Moogeh Baharnoori et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.